Literature DB >> 9390209

Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma.

H Nagahama1, S Okada, T Okusaka, H Ishii, M Ikeda, H Nakasuka, M Yoshimori.   

Abstract

Chemotherapy is of limited value in the treatment of hepatocellular carcinoma (HCC), since there are no established chemotherapeutic regimens proven to be effective. The aim of the present study was to determine predictive factors for tumor response to systemic chemotherapy in HCC patients. The relationship between patients' characteristics and tumor response was examined in 147 previously untreated HCC patients receiving systemic chemotherapy. Ten patients showed partial response (PR) and none showed complete response (CR). The response rate for all single anticancer agents was less than 10% and the overall response rate was 6.8%. The response rate in patients with unilateral HCC was significantly higher than in those with bilateral HCC. However, there were no responders among patients with a performance status of 2-3, ascites, a tumor occupying more than 50% of the entire liver, tumor thrombus in the main portal trunk or a serum bilirubin level of more than 2.0 mg/dl. There was a close relationship between patients' characteristics and tumor response. It is concluded that patients with fairly advanced HCC and/or poor hepatic reserve should not be given systemic chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390209     DOI: 10.1093/jjco/27.5.321

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  14 in total

1.  Cyproheptadine use in hepatocellular carcinoma.

Authors:  Mao-Chih Hsieh; Wei-Hua Lee; Alexander Th Wu; Jyh-Ming Chow; Chia-Lun Chang; Kevin Sheng-Po Yuan; Szu-Yuan Wu
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  Lenvatinib in Advanced Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-08-29       Impact factor: 11.740

3.  Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-02-15       Impact factor: 11.740

4.  Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.

Authors:  Toru Ishikawa
Journal:  World J Hepatol       Date:  2009-10-31

Review 5.  Immunomodulation in hepatocellular cancer.

Authors:  Sunyoung Lee; Matthew Loecher; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2018-02

Review 6.  Current systemic treatment of hepatocellular carcinoma: A review of the literature.

Authors:  Kai-Wen Chen; Tzu-Ming Ou; Chin-Wen Hsu; Chi-Ting Horng; Ching-Chang Lee; Yuh-Yuan Tsai; Chi-Chang Tsai; Yi-Sheng Liou; Chen-Chieh Yang; Chao-Wen Hsueh; Wu-Hsien Kuo
Journal:  World J Hepatol       Date:  2015-06-08

7.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

Review 8.  Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.

Authors:  Khanh Nguyen; Kerri Jack; Weijing Sun
Journal:  Diseases       Date:  2015-12-25

9.  Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.

Authors:  Mitsuharu Hanada; Akemi Baba; Yasuyuki Tsutsumishita; Toshihiro Noguchi; Takashi Yamaoka; Nobuyoshi Chiba; Fumio Nishikaku
Journal:  Cancer Chemother Pharmacol       Date:  2008-12-24       Impact factor: 3.333

Review 10.  Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.

Authors:  So Young Yoo; Narayanasamy Badrinath; Hyun Young Woo; Jeong Heo
Journal:  Mediators Inflamm       Date:  2017-04-20       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.